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This manuscript describes a novel mechanism of renal tubular damage and chronic 
kidney disease involving the formation of unique intramitochondrial protein 
aggregates. The disease results from monoallelic mutations in the gene "glycine 
amidinotransferase" (GATM), a proximal tubular enzyme in the creatine biosynthetic 
pathway. All disease related GATM mutations create an additional interaction interface 
within the GATM protein, promoting its linear aggregation. Aggregates-containing 
mitochondria in proximal tubular cells are associated with elevated production of 
reactive oxygen species, initiation of an inflammatory response and increased cell 
death. These data establish a link between intramitochondrial GATM aggregates, renal 
Fanconi syndrome and chronic kidney disease.  
Page 3 of 42
ScholarOne support: 888-503-1050


































































Background: For many cases of kidney failure, the cause and underlying defect remain 
unknown. Here we describe a novel mechanism of renal Fanconi syndrome and chronic 
kidney disease involving the formation of unique intramitochondrial protein aggregates. 
Methods: We clinically and genetically characterized members of five families with 
autosomal dominant renal Fanconi syndrome and kidney failure. We performed genome-
wide linkage analysis, sequencing and expression studies in kidney biopsies and renal cells, 
along with knockout mouse studies and evaluations of mitochondrial morphology and 
function. Structural studies examined the effects of recognized mutations. 
Results: The renal disease in our patients resulted from monoallelic mutations in the gene 
"glycine amidinotransferase" (GATM), a renal proximal tubular enzyme in the creatine 
biosynthetic pathway that is otherwise associated with a recessive disorder of creatine 
deficiency. The particular GATM mutations, identified in 28 members of five families with 
progressive kidney failure, created an additional interaction interface within the GATM 
protein, promoting its linear aggregation. Aggregates-containing mitochondria were 
elongated and associated with increased ROS production, activation of the NLRP3 
inflammasome, enhanced expression of the profibrotic cytokine IL-18 and increased cell 
death. 
Conclusion: In this novel genetic disorder, fully penetrant heterozygous missense mutations 
in GATM trigger intramitochondrial fibrillary deposition of GATM and lead to elongated and 
abnormal mitochondria. We speculate that this renal proximal tubular mitochondrial 
pathology initiates a response from the inflammasome with subsequent development of 
kidney fibrosis.  
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"Chronic kidney disease" (CKD) is a worldwide health problem and comprises 
heterogeneous disorders affecting kidney structure and function.1 The underlying 
pathogenesis is complex and, in many cases, involves genetic predisposition.  
 Here, we describe in five extended families a novel form of autosomal dominant 
kidney disease. The disease is characterized by renal tubular Fanconi syndrome early in life 
followed by progression to renal glomerular failure in mid-adulthood. All our patients show 
monoallelic mutations in the gene GATM that create an additional protein-protein interaction 
surface at which the protein multimerizes leading to large mitochondrial protein aggregates. 
The appearance of these aggregates was paralleled by increased production of reactive 
oxygen species, inflammatory signals, cell death, and renal fibrosis. This new disease 
expands the gamut of etiologies of tubuloglomerular disease. 
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Full details of the methods can be found in the Supplemental Data. 
Patients 
Members of two families were admitted to the NIH Clinical Center and enrolled in clinical 
protocols 1-HG-0106 or 76-HG-0238. Three further families were evaluated in Cambridge, 
Oxford, and London. All participating individuals or their parents gave written, informed 
consent. All investigations, including genetic studies, were approved by the respective 
Institutional Review Boards and conducted according to the principles of the Declaration of 
Helsinki. 
 The diagnosis of renal Fanconi syndrome and kidney failure was established by 
routine laboratory investigations of urine and blood samples. Clinical details concerning four 
of these five families have been published previously.2-10 Kidney samples were acquired from 
two affected individuals. One patient was biopsied at age 21, another patient died at age of 
65 due to end stage renal failure and the kidney was studied at autopsy. Electron 
microscopic studies and histological stainings were performed using established 
procedures.11 One affected and one unaffected adult underwent brain 1H-NMR spectroscopy 
utilizing standard diagnostic procedures.12 
 
Genetic studies 
We previously linked the locus for this trait in an extended US family (Figure 1A, Family 1) to 
a region on chromosome 15q.13 To prove linkage to the same locus, we performed additional 
linkage studies in our other families showing the same trait. To this end, DNA was isolated 
from whole blood using standard procedures and was genotyped with 2000 highly 
polymorphic STS markers by deCODE Genetics (Iceland) for families 3, 4, 5 or commercially 
available SNP chips (Affymetrix) for family 2 (Figure 1A). Multipoint parametric linkage 
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analysis was performed using established procedures for families 2-5.12 Initial gene discovery 
was performed by either targeted capture and next generation sequencing (The Eastern 
Sequence and Informatics Hub, University of Cambridge, UK) or whole exome sequencing 
(SeqWright, Inc, Houston, TX, USA) in six affected individuals from four of our families. 
Recognized sequence variants within the linked region were examined for segregation in all 
available affected and unaffected family members and confirmed by Sanger sequencing. 
Observed novel sequence variants were assessed for uniqueness and evolutionary 
conservation in various species. Public databases (dbSNP, 1000 Genomes, exome 
database) were also interrogated. 
 
Renal proximal tubular cell model and kidney imaging 
A permanently transfected, inducible renal proximal tubular cell line derived from LLC-PK1 
cells was created for each patient GATM mutation using recombinant technology. LLC-PK1 
cells are an established model and reliably express many properties of the renal proximal 
tubule.11 For in-situ immunostaining, subcellular studies, metabolic studies, expression 
studies and electron microscopy, cells and tissues were prepared and investigated using 
established procedures. Specifically, the renal and intracellular localization of GATM was 
studied. Changes in expression of relevant genes were studied using established real-time 
PCR technology. 
 
Gatm knockout mice 
All animal experiments were performed according to the guidelines for the care and use of 
laboratory animals published by the US National Institutes of Health and were approved by 
the local councils for animal care according to the German law for animal care. We 
previously generated Gatm knockout mice to study the biochemical function of this 
mitochondrial protein.14 Mutant mice were viable, without detectable gross phenotypic 
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defects, but dystrophic. Urinary metabolites were assessed in knockout and control mice 
using established analytic procedures. 
 
Structural studies 
To test the hypothesis of mutation-mediated aggregation of GATM, we performed molecular 
dynamics simulations on the wildtype monomer and on the four mutants. Modelling of 
possible protein-protein interaction surfaces (GRAMM-X; 
vakser.bioinformatics.ku.edu/resources/gramm/grammx/) started with the structure of the 
wildtype monomer (pdb: 1JDW). 
 
Statistical methods 
Data are presented as the mean ± SEM (standard error of the mean) and were analyzed 
using one-way ANOVA or Student's t-test if not specified otherwise. For all analysis, if not 
stated otherwise, a p-value of 0.05 was accepted to indicate statistical significance. 
Statistical analysis was performed using GraphPad Prism 5, OriginPro, and SPSS software. 
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All affected individuals from five extended families (Figure 1A) exhibited an autosomal 
dominant form of "chronic kidney disease" (CKD). During childhood, all patients developed a 
renal Fanconi syndrome with glucosuria, hyperphosphaturia, generalized 
hyperaminoaciduria, low molecular weight proteinuria and metabolic acidosis, but without 
debilitating rickets or bone deformities. As an example, at age 18 months the youngest 
affected child studied exhibited laboratory findings typical of renal Fanconi syndrome but no 
glomerular compromise (Supplemental Table S1). During late adolescence or adulthood, 
increased plasma creatinine became apparent and patients developed renal fibrosis and 
kidney failure, with the need for transplant or dialysis in the third to sixth decade of life. A 
graph illustrating the decline in kidney function in relation to age is shown in Supplemental 
Figure S1. Premature deaths due to compromised glomerular kidney function occurred in 
several families. No extra-renal clinical findings were noted. 
 
Genetic analyses 
In all six affected individuals initially studied, sequencing of all genes within the linked locus 
on chromosome 15 (Figure 1B) showed mutations in a single gene, identified as "glycine 
amidinotransferase", GATM. Subsequent sequencing of all 28 clinically affected individuals 
showed each had one heterozygous missense mutation in GATM. We identified four 
previously unreported heterozygous missense mutations of evolutionary conserved amino 
acid residues in GATM (c.958C>T, p.P320S; c.1006A>G, p.T336A; c.1007C>T, p.T336I; 
c.1022C>T, p.P341L). In each family, one variant segregated with the disorder and was fully 
penetrant. None of the unaffected family members carried any of these GATM mutations. 
One family showed a de novo heterozygous mutation in affected offspring confirmed by 
haplotype analysis, which was passed on to the next generation (Figure 1A, Family 4). 
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Patients' biopsies showed the morphological correlate of kidney fibrosis on routine staining 
(Figure 1 C-F). In normal kidneys, GATM was found in mitochondria of proximal tubules, 
particularly in the early segments.15 In a patient’s kidney biopsy, electron microscopy and 
GATM-specific immunogold staining of renal proximal tubules revealed drastically enlarged 
mitochondria containing pathological GATM protein aggregates (Figure 2 A-C). 
 To further explore the pathophysiological mechanisms of this particular mitochondrial 
phenotype, we over-expressed wildtype or mutant GATM in a renal proximal tubule cell line, 
LLC-PK1. Normal mitochondrial morphology was observed in cells expressing wildtype 
GATM, but abnormal and elongated mitochondria were observed in the cells expressing the 
GATM T336A mutant (Figure 2D-F). Similar findings were present in cells transfected with 
GATM mutants T336I, P341L, and P320S (unpublished data). Immunogold electron 
microscopy of cells over-expressing mutant GATM demonstrated drastically enlarged 
mitochondria containing GATM-positive fibrillary aggregates, similar to the deposits observed 
in proximal tubules of patients' biopsies (Figure 2G-I). 
 
Structural studies 
We performed in silico structural studies of GATM, which contains ten X-ray crystallographic 
structures in the protein data bank.16 The 423-amino acid GATM protein is built around a 
central core formed by five antiparallel beta sheets (B1-B5) disposed around a five-fold axis 
of symmetry. Such a structure is potentially prone to protein-protein aggregation due to the 
presence of the five solvent-exposed beta sheets. In addition to the domain of five-fold 
symmetry, the GATM protein hosts one additional domain composed of four alpha helices 
and a beta hairpin involved in formation of the wildtype dimer. Assembly of the physiological 
GATM dimer involves the two facing beta sheets (B2) disposed in parallel with an angle of 
Page 10 of 42
ScholarOne support: 888-503-1050
































































approximately 45° with respect to each other, harbo ring the catalytic enzymatic activity 
domain (Figure 2J, K). 
 The four disease-related mutations involve three amino acids conserved through 
evolution, i.e., Pro320, Pro341, and Thr336. All three are located on the surface around 
sheet B4, which is located opposite to the B2 surface (Figure 2K, L). Thus, these mutations 
could impair the proper folding of the B4 surface. In fact, structure simulations of these four 
GATM mutants predicted increased mobility of the same region for each of them, 
predisposing the mutated B4 region to form an additional interaction site. Specifically, the 
presence of two opposite dimerization surfaces, B2 and B4, would support the formation of 
linear multimers, with each mutant GATM monomer linked to two protein partners by two 
dimerization interfaces, i.e. the existing “physiological” “B2-B2” and the “de novo” 
pathological “B4-B4” interface (Figure 2M). 
 
Gatm-/- mouse studies 
We employed Gatm-/- mice to determine whether mitochondrial GATM haploinsufficiency (i.e. 
decreased GATM activity) was likely to have caused our families’ renal Fanconi syndrome. 
No aminoaciduria and no glucosuria was observed in these mice (Supplemental Figure S2), 
indicating that lack of GATM did not significantly affect renal proximal tubular function. 
Rather, we propose that mutant GATM proteins within mitochondria trigger a pathological 
cascade inside and outside the proximal tubules, resulting in our patients’ signs and 
symptoms.  
 
Intramitochondrial deposits impair mitochondrial degradation and elicit an 
inflammatory response 
In a next set of experiments we investigated mitochondrial turnover in cells over-expressing 
mutant GATM. Electron micrographs of these cells indicated that the fibrillary GATM deposits 
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might impair mitochondrial fission and, thus, mitochondrial degradation (Figure 2I). Indeed, 
over-expression of mutant GATM led to a reduced mitochondrial turnover rate in our cell 
model. This was evidenced by the presence of GATM-positive enlarged mitochondria even 8 
weeks after induction of GATM T336A expression was discontinued (Figure 3A-H).  
 Furthermore, we explored possible links between mitochondrial GATM protein 
deposits and pathways inducing tubular damage and renal fibrosis. The mitochondrial 
phenotype in our cell model was associated with an increased production of reactive oxygen 
species (ROS) (Figure 3I). Excess ROS generation leads to oxidative stress and triggers - in 
concert with other factors - the inflammasome.17-20 In fact, LLC-PK1 cells carrying 
mitochondrial GATM deposits showed significantly elevated mRNA expression of both the 
inflammasome component NLRP3 and Interleukin 18 (IL-18), a cytokine known to promote 
renal fibrosis (Figure 3J, K).21, 22 IL-18 protein was also elevated as measured by ELISA 
(Figure 3L). Moreover, those cells exhibited increased fibronectin and smooth muscle actin 
mRNA levels (Figure 4A, B) as well as an increased rate of cell death (Figure 4C, D). These 
findings strongly suggest that mitochondrial GATM aggregates led to activation of 
components of the inflammasome and release of profibrotic factors, thereby providing a 




Since mutant GATM protein resulted in pathogenic intramitochondrial deposits in renal 
proximal tubular cells, we investigated means to reduce GATM production. GATM 
expression was reported to be negatively feedback regulated by creatine in rats,23 so we 
supplemented wildtype mice with 1% creatine in their drinking water for 1 week. This protocol 
reduced renal GATM mRNA expression by 27% and GATM protein by 58% (Figure 4E, F), 
corroborating previous findings.23 Hence, creatine supplementation could serve as an 
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intervention to suppress the endogenous production of mutated GATM protein and to retard 





"Chronic kidney disease" (CKD) affects 8-16% of the adult population and comprises 
heterogeneous disorders of unknown etiology affecting kidney structure and function.1, 24, 25 
Here, we provide genetic, histological, cell biological, and structural evidence for the 
association between monoallelic GATM mutations and a genetic disorder characterized by 
renal Fanconi syndrome and progressive kidney failure. 
 GATM encodes the mitochondrial enzyme "glycine amidinotransferase" ("L-
arginine:glycine amidinotransferase", also known as AGAT), which catalyzes the transfer of a 
guanidino group from L-arginine to glycine, resulting in guanidinoacetic acid, the immediate 
precursor of creatine.16, 26, 27 GATM is expressed most prominently in kidney, liver, pancreas 
and brain. Recessive loss-of-function mutations of GATM result in "cerebral creatine 
deficiency syndrome", a rare inborn error of creatine synthesis characterized by severe 
neurological impairment.12, 28 A Gatm-/- mouse model also showed neurological symptoms 
caused by creatine deficiency,14 but had normal kidney function (Supplemental Figure S2). In 
contrast to patients with "cerebral creatine deficiency syndrome", none of our patients 
showed extra-renal symptoms. The one patient studied by brain 1H-NMR spectroscopy had a 
normal creatine peak (Supplemental Figure S3), indicating that the disorder in our patients 
was not related to creatine deficiency. 
 Histological examinations of patients’ kidney biopsies revealed a dramatic 
mitochondrial phenotype associated with GATM mutations. Mitochondria of proximal tubular 
cells were drastically enlarged and filled with filament-like deposits. This phenotype was also 
observed in a LLC-PK1 cell model over-expressing GATM mutants. Immunogold studies on 
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a patient biopsy and LLC-PK1 cells demonstrated that these deposits were composed of 
mutant GATM protein, and in silico structural studies provided an explanation. Heterozygous 
GATM mutations in a particular region of the enzyme led to the creation of an additional de 
novo interaction surface, causing intramitochondrial “multimeric” aggregation. This gain-of-
function effect of the mutations was in line with the dominant inheritance of the disease.   
 Mitochondrial fission results in smaller mitochondria and, thereby, facilitates removal 
and degradation of aged mitochondria by mitophagy.29 Intramitochondrial aggregates of 
mutant GATM apparently impaired mitochondrial division, leading to pathologically enlarged 
and aged mitochondria which could no longer be removed by mitophagy. In our LLC-PK1 cell 
model, mitochondria with GATM deposits were still present even 8 weeks after GATM mRNA 
expression was discontinued. The long persistence of deposits contrasted with the 
physiological turnover rate of mitochondria, estimated to be 2-4 weeks.29 These data suggest 
that the long fibrillary deposits of mutant GATM, once aggregated, escape cellular 
degradation, prevent mitochondrial fission and lead to enlarged, aged mitochondria. 
 Aged mitochondria as well as non-degradable deposits and crystalline structures are 
known to trigger an inflammatory response and activate the NLRP3 inflammasome.17, 18, 30-33 
In agreement with these reports, the appearance of mutant GATM aggregates in our cell 
model was paralleled by enhanced inflammatory markers: NLRP3 and its downstream 
signaling molecule Interleukin 18 (IL-18) were strongly elevated. We also found evidence of 
increased reactive oxygen species (ROS) production in mutated cells. Mitochondria are a 
major source of intracellular ROS, and excess ROS generation is known to lead to oxidative 
stress and trigger the inflammasome, too.34, 35 In addition, over-expression of mutant GATM 
led to an increased rate of cell death and enhanced expression of the fibrosis marker 
fibronectin and smooth muscle actin. In line with this profound in vitro cytopathological 
phenotype, immunofluorescence studies in kidney biopsies from our patients revealed 
significant interstitial fibrosis with myofibroblasts surrounding renal tubules and thickening of 
tubular basement membranes, eventually leading to kidney failure.20, 21, 33 
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 Taken together, we provide evidence that intramitochondrial aggregates consisting of 
mutated glycine amidinotransferase (GATM) protein are causative for an autosomal 
dominant form of renal Fanconi syndrome and chronic kidney disease. This finding extends 
the spectrum of disorders associated with pathological protein aggregates beyond 
neurodegenerative disorders such as Alzheimer’s disease. The disease also illustrates the 
critical role mitochondria can play in initiating devastating profibrotic signaling cascades. This 
may have implications for understanding the pathophysiology of chronic kidney disease. An 
association of genetic variation in the GATM gene to plasma creatinine levels was previously 
suggested by genome-wide association studies.36-38 
 Cohorts of patients with kidney failure or renal insufficiency deserve up-to-date 
genetic diagnostic procedures, with attention to de novo mutations. Sequencing of GATM 
should be considered in patients with kidney failure, particularly adults with or without familial 
occurrence. Moreover, kidney biopsies that do not yield a diagnosis based upon standard 
histology should be considered for ultrastructural analysis, with consideration of tubular 
pathology rather than an evaluation limited to the glomerulus and interstitium. Finally, for 
patients with autosomal dominant GATM mutations, only 50% of the GATM protein is 
abnormal, and biosynthesis of creatine is negatively feedback regulated by its product.23 
Hence, creatine supplementation could serve as a pharmacological intervention to suppress 
the endogenous production of mutated GATM protein, which triggers the cascade leading 




All authors together generated and gathered the patient, animal, genetic and molecular data 
and analyzed the data. William A Gahl, Robert J Unwin, Richard Warth, and Robert Kleta 
(overall responsible) vouch for the data and the analysis. All authors helped writing the 
paper, and all together decided to publish this paper.  
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Figure 1: Genetic analysis and kidney histology 
(A) Pedigrees of families with renal Fanconi syndrome and kidney failure. Squares indicate 
males and circles females; a filled symbol indicates that the person is affected; deceased 
individuals are drawn with a diagonal line through the symbol. An asterisk indicates that the 
person contributed to linkage and sequencing studies. Note de novo “appearance” of the 
disease in family 4.  
(B) Multipoint parametric linkage analysis for families 3, 4, 5 for chromosome 15. The y-axis 
shows the LOD score, and the x-axis gives the genetic distance in cM. Note significant 
linkage (LOD score > 3) in the region of 40 - 60 cM.  
(C) Masson-Goldner staining of a renal Fanconi and kidney failure patient’s post mortem 
kidney specimen. Connective tissue is stained light green. This specimen shows the highly 
fibrotic terminal kidney morphology of the disease. The cortex is shrunken and contains very 
few proximal tubules. Most glomeruli are atrophic and fibrotic (upper left corner), some 
appear intact (lower right corner). Scale bar: 50 µm.  
(D) Immunofluorescence of same specimen as in (C). α-smooth muscle actin (a marker for 
myofibroblasts) stains red, and nuclei blue. The Bowman capsule of the glomerulus contains 
myofibroblasts (red), which suggests that the kidney damage is not restricted to proximal 
tubules during the final stage of the disease. Scale bar: 20 µm.  
(E) Immunofluorescence of same specimen as in (C). GATM stains green, α-smooth muscle 
actin (a marker for myofibroblasts) red, and nuclei blue. The picture shows a proximal tubule 
with GATM positive epithelium (asterisk). Several layers of myofibroblasts (arrowhead) 
surround the tubule. Scale bar: 20 µm.  
Page 23 of 42
ScholarOne support: 888-503-1050
































































(F) Electron microscopy of same specimen as in (C). Most tubules show an extremely thick 
basal membrane containing myofibroblasts (arrowhead). Tubular epithelium is marked by an 
asterisk. Scale bar: 7 µm. 
 
Figure 2: Mitochondrial morphology and structural analysis 
(A) Electron microscopy of a proximal tubular cell from a patient's biopsy showing giant 
mitochondria with deposits (arrows). Scale bar: 1000 nm.  
(B) GATM-immunogold electron microscopy of a proximal tubular cell with an enlarged, 
filament-containing mitochondrion from a patient's biopsy. Asterisk indicates proximal tubule 
brush border membrane. Scale bar: 2 µm.  
(C) Higher magnification of (B) (white square). Note packed linear deposits with 6 nm GATM-
specific gold particles attached (arrow heads). Scale bar: 200 nm.  
(D) Immunofluorescence of LLC-PK1 renal proximal tubular cells with induced expression (3 
days) of wildtype GATM (green). Normal mitochondria in red (mitotracker), nuclei in blue, 
scale bar: 20 µm.  
(E) Immunofluorescence of LLC-PK1 cells with induced expression (3 days) of mutant GATM 
(T336A, green) and abnormal mitochondria (red). Nuclei in blue, scale bar: 20 µm.  
(F) Immunofluorescence of LLC-PK1 cells with induced expression (9 weeks) of mutant 
GATM (green) causing large deposits. Nucleus in blue, scale bar: 10 µm.  
(G) Electron microscopy of an LLC-PK1 cell overexpressing the T336A mutant. Within the 
mitochondrial matrix, GATM filaments were aligned in a parallel manner (arrow heads). 
Cristae are marked by arrows, scale bar: 500 nm.  
(H) Immunogold electron microscopy of mutant GATM (T336A) in LLC-PK1 cells. 
Intramitochondrial gold particles attached to linear long aggregates (arrow heads) indicate 
that GATM comprises these deposits. Scale bar: 100 nm.  
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(I) Electron microscopy of LLC-PK1 cells overexpressing the P341L mutant in LLC-PK1 cells. 
A GATM filament appears to prevent mitochondrial fission (arrow). Scale bar: 500 nm.  
(J) Wildtype GATM in two orientations rotated by 90° a round the horizontal axis, colored by 
secondary structures: yellow β sheets, green loops, and red α helices. In the left orientation, 
the five-fold symmetry with the five β sheets B1-B5 is visible. In the right orientation, the β 
hairpin involved in wildtype homo-dimer formation becomes visible.  
(K) The wildtype homo-dimer is stabilized by interaction of β sheets B2. (L) Mutated GATM: 
Surface of the B4 module (green) shows the mutated amino acids in red. Remainder of 
GATM is blue. Localization of all observed mutations (p.P320S, p.T336A, p.T336I, and 
p.P341L) on the same surface leads to the appearance of a novel additional interaction site.  
(M) Proposed disease mechanism in which the creation of an additional mutation-related 
novel interaction site in the B4 module can lead to aggregation of GATM multimers instead of 
the physiological homo-dimer; B2 denotes physiological interaction site forming 
enzymatically active GATM. B4 denotes additional interaction site opposite the B2 module 
mediating longitudinal GATM aggregation. Monomers carrying the mutation are shown in 
green and cyan, respectively. 
 
Figure 3: Giant mitochondria and activation of the NLRP3 inflammasome 
(A-D) LLC-PK1 cells, induced with tetracycline for two weeks, over-expressed wildtype 
GATM. Induction was discontinued to stop further over-expression. GATM was immuno-
stained immediately after discontinuing tetracycline (A), after 4 (B), 6 (C) and 8 weeks (D). At 
week 4, the GATM signal (green) was very faint and at week 6, GATM was no longer 
detected. Nuclei in blue, scale bar: 20 µm.  
(E-H) Protocol as in (A – D), but with LLC-PK1 cells over-expressing the T336A mutant. 
Within eight weeks, the cells were not able to degrade GATM deposits and giant 
mitochondria. Scale bar: 20 µm.  
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(I) Live-cell-imaging of mitochondrial reactive oxygen species (ROS) production in LLC-PK1 
cells over-expressing wildtype GATM (n = 6) or the T336A mutant (n = 6). ROS production 
rate was measured with the mitochondrial-targeted superoxide probe CellROX Deep Red. 
The slopes of the linear regression curves were significantly different (ANCOVA; p=0.0065).  
(J, K) Realtime PCR in LLC-PK1 vector control cells (vector), cells over-expressing wildtype 
GATM (wildtype) and the T336A mutant (T336A); n=20 dishes for each group; mean values 
± SEM. Values were normalized to β-actin mRNA expression.  
(J) Realtime PCR of the inflammasome component NLRP3. * significantly different from 
vector control cells (ANOVA, Bonferroni test, p<0.001), # significantly different from wildtype 
GATM expressing cells (p<0.001).  
(K) Realtime PCR of the profibrotic cytokine IL-18. * significantly different from vector control 
cells (ANOVA, Bonferroni test, p<0.001), # significantly different from wildtype GATM 
expressing cells (p<0.001).  
(L) IL-18 ELISA in total cell lysates of LLC-PK1 cells over-expressing wildtype GATM (n = 3) 
or the T336A mutant (n = 3). Data were normalized to total protein content. Over-expression 
of the T336A mutant led to increased IL-18 synthesis (unpaired, two-sided t-test p=0.001). 
 
Figure 4: Fibrosis, cell death, and possible therapeutic intervention 
(A, B) Realtime PCR in LLC-PK1 vector control cells (vector), cells over-expressing wildtype 
GATM (wildtype) and the T336A mutant (T336A); n=20 dishes for each group; mean values 
± SEM. Values were normalized to β-actin expression. (A) Realtime PCR of fibronectin 1 
(FN1), * significantly different from vector control cells (ANOVA, Bonferroni test p<0.001), # 
significantly different from wildtype GATM expressing cells (p=0.003). Values of vector 
controls cells were not different from wildtype GATM expressing cells (p=0.0502). (B) 
Realtime PCR of α smooth muscle actin 2 (ACTA2). * significantly different from vector 
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control cells (ANOVA, Bonferroni test p<0.001), # significantly different from wildtype GATM 
expressing cells (p<0.001).  
(C) Lactate dehydrogenase (LDH) release as a measure of cell death in LLC-PK1 cells over-
expressing wildtype GATM (n = 3) or the T336A mutant (n = 3). After induction (3 weeks), the 
cell medium remained unchanged and samples were taken on day 2, 3, and 4. ANOVA with 
post-hoc student´s t-tests corrected for multiple testing by the Bonferroni method; p-values 
were 0.0039 (day 2), <0.0001 (day 3), and <0.0001 (day 4).  
(D) Cell death in LLC-PK1 cells over-expressing the T336A mutant (induced for seven 
weeks). The remains of a dead cell with giant mitochondria (green). The nucleus (red) is 
fragmented (arrows) indicating cell death. Scale bar: 10 µm.  
(E, F) Effect of oral creatine supplementation on Gatm expression. Wildtype mice were 
supplemented with 1% creatine in their drinking water (n = 4) for one week; control mice 
received tap water (n = 4). Renal Gatm mRNA and protein expression were determined 
using realtime PCR (E) and Western blot (F). Creatine supplementation led to a reduction of 
mRNA and protein expression (unpaired, two-sided t-tests, p=0.013 and p=0.029, 
respectively). Values normalized to β-actin mRNA or total protein expression. 
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Supplementary Materials and Methods 
1H-NMR creatine spectroscopy 
1H-NMR spectroscopy of body fluids shows the majority of proton-containing 
compounds and therefore can provide an overall view of metabolism.1 1H-NMR spectrum 
provides a characteristic ‘fingerprint’ of almost all proton-containing metabolites. In these 
spectra, the spectral parameters chemical shift, spin-spin coupling, and signal intensity 
are important for body fluid analysis. The peak area or signal intensity of a resonance in 
a 1H-NMR spectrum is proportional to the number of protons contributing to the signal 
when appropriate experimental conditions are used. Since the peak area is proportional 
to the number of protons contributing to the signal, it is also proportional to the 
concentration of the molecule concerned. Therefore, it is possible to use 1H-NMR 
spectroscopy for metabolite quantification. The sensitivity of the technique is in the low 
micromolar range for most metabolites. It is well suited to detect creatine in urine, 
plasma, and cerebrospinal fluid as well as in-vivo within the brain (overview and details 
taken from 2). Here, 1H-NMR spectra were acquired on an Achieva 3T MR scanner 
(Philips, Best, The Netherlands) using a PRESS sequence (TR=2000 ms, TE=35 ms, 
128 averages, 15x15x15 mm voxel) and processed in LCModel (Provencher, Magn 
Reson Med 30, 672 (1993)), referencing to the unsuppressed water. 
 
Renal proximal tubular cell model  
A permanently transfected, inducible renal proximal tubular cell line derived from 
LLC-PK1 cells was created for each patient GATM mutation using recombinant 
technology. LLC-PK1 cells are an established model and reliably express many 
properties of the renal proximal tubule.3 We previously had established tetracycline-
inducible stable transfected LLC-PK1 cells that were obtained using the Flp-in T-Rex 
system (Invitrogen, Paisley, UK) containing the constructs pFRT/lacZeo and 
pcDNA/5/TR (JCRB0060, Health Science Research Resources Bank, Tokyo, Japan). 
These cell lines and derived cells were maintained in 1 g/L glucose DMEM (PAA 
laboratories, E15-005, Yeovil, UK) medium with 8% fetal bovine serum (PAA 
laboratories, A15-109, Yeovil, UK), 2 mM L-glutamine (PAA laboratories, M11-006, 
Yeovil, UK), penicillin (100 U/ml)/streptomycin (100 µg/ml) (PAA laboratories, P11-010, 
Yeovil, UK). 
The human GATM coding region was obtained from a Trueclone full length cDNA 
clone (sc321307, NM_001482.1; Origene Technologies; Rockville, MD, USA). The 
Origene vector containing the full length GATM cDNA was subcloned into the NotI site of 
the pcDNA5FRT/TO vector. The patients’ mutations c.958C>T (p.P320S), c.1006A>G 
(p.T336A), c.1007C>T (p.T336I), and c.1022C>T (p.P341L), were inserted via site-
directed mutagenesis (QuikChange II, Stratagene, Santa Clara, CA USA). To this end 
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The full length wildtype and mutant cDNA clones were all sequence-verified. The 
stable transfected Frt-1 cells containing the pcDNA/5/TR construct were cotransfected at 
a ratio of 9:1 (w/w) circularized pOG44:pcDNA5/FRT/TO/GATM, 
pOG44:pcDNA5/FRT/TO/T336AGATM, pOG44:pcDNA5/FRT/TO/T336IGATM, 
pOG44:pcDNA5/FRT/TO/P341LGATM, or pOG44:pcDNA5/FRT/TO/P320SGATM. 
Transfection was performed using lipofectamine 2000 (Thermofisher Scientific, 
11668027, UK) according to the protocol of the manufacturer. The transfected cells were 
incubated for four weeks in selection medium containing 500 µg/ml hygromycin-B. 
Several clones were obtained for cells transfected with these constructs. Incorporation of 
the constructs in the genomic DNA was demonstrated by PCR analysis, and 
subsequently sequence analysis of the full coding region of human GATM. These PCR 
and sequence conditions are available on request. Induced expression of human GATM 
was achieved using 1 µg/ml tetracycline (Applichem/VWR, A1685, Lutterworth, UK) for 
each of the clones. To this end, real-time PCR (conditions used available on request), 
Western analysis (conditions used available on request) and immunohistochemical 
analysis were utilized. For all functional analyses described, a single clone was used. 
Upon induction with 1 µg/ml tetracycline these clones showed equal expression of 
human GATM.  
 
RNA isolation 
Inducible LLC-PK1 cells were seeded in cell medium (RPMI medium 1640 with 11.1 
mM glucose (Gibco Cell Culture Systems - Invitrogen, Karlsruhe, Germany), FCS 10%, 
penicillin G 5 I.U., streptomycin 50 µg/ml, sodium hexanoate 5 mM). To induce the 
expression system of the cells, tetracycline (1 µg/ml) was added to the medium. Cells 
were cultured and induced for three weeks until RNA was isolated. Medium was 
changed every other day. Total RNA from inducible LLC-PK1 cells was isolated using a 
column based kit optimized for the purification from small amounts of tissue according to 
the manual (RNeasy Micro Kit, Qiagen, Hilden, Germany). The RNA concentration was 
quantified with a photometer (NanoDrop ND-1000, PEQLAB Biotechnologie GmbH, 
Erlangen, Germany). Quality of the RNA used for real-time RT-PCR was tested by 
agarose electrophoresis. 
 
Quantitative realtime PCR 
Reverse transcription with M-MLV-RT (Promega GmbH, Mannheim, Germany) and 
random primers (Fermentas GmbH, St. Leon-Rot, Germany) was done using 1 µg total 
RNA to generate single-stranded cDNA. Relevant contamination with genomic DNA was 
excluded by negative control reactions without the reverse transcriptase enzyme (-RT). 
Realtime PCR of cDNA samples was performed on a LightCycler 480 device (Roche, 
Basel, Switzerland) using specific and, wherever applicable, intron-spanning primers, 
and a SYBR® Green mastermix (Roche, Basel, Switzerland). Target gene expression 
levels were quantified relative to beta-actin expression under consideration of PCR 
efficiencies calculated on the basis of standard dilution curves. The specificity of PCR 
amplifications was verified by agarose electrophoresis and melting curve analysis. 
Primer sequences (Life Technologies GmbH, Darmstadt, Germany) are listed in Table 
S3.  
For realtime-PCR experiments in LLC-PK1 cells (porcine NLRP3, porcine IL-18, 
porcine FN1, porcine ACTA2, Fig. 3J, K and Fig. 4A, B), n=20 petri dishes of three 
independent experimental series were used (each series with vector control cells and 
cells over-expressing wildtype GATM or the T336A mutant). For realtime PCR 
experiments determining the murine GATM expression in mouse kidneys after a high 
creatine diet, n=4 treated and n=4 untreated animals were used. Data are shown as 
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mean values ± standard error of the mean (SEM); “n” stands for the number of 
observations. ANOVA followed by a Bonferroni Test (OriginPro, Northampton, MA 
01060, USA) (Fig. 3J, K and Fig. 4A, B) or t-test (Fig. 4E) were used to determine 
statistical significance. A p-value of 0.05 was accepted to indicate statistical significance.  
 
Immunofluorescence on inducible LLC-PK1 cells 
Inducible LLC-PK1 cells were grown on glass coverslips and induced with 
tetracycline (1 µg/ml) for at least 24 h. For mitochondrial staining, MitoTracker Orange 
CMTMRos (Invitrogen, Karlsruhe, Germany) was added (1:5000) to the medium and 
incubated at 37°C, 5% CO 2, for 30 min. After washing with Ringer’s solution, cells were 
fixated for 15 min with 3% paraformaldehyde in PBS (phosphate buffered saline pH 7.4). 
Cells were rinsed twice with PBS and afterwards incubated in PBS containing 0.1% SDS 
for 5 min to unmask the epitopes followed by another wash with PBS for 2 x 5 min. 
Primary antibodies were applied for 1 h. Primary and secondary antibodies were diluted 
in PBS with 0.04% Triton X-100 (Sigma, Taufkirchen, Germany). After washing twice 
(PBS, 5 min), cells were incubated for 1 h with the secondary antibody and HOE33342 
to stain the nuclei. After a final washing step (PBS, 2 x 5 min), the glass coverslips with 
the cells were mounted on slides with fluorescent-free glycergel mounting medium 
(DakoCytomation, Hamburg, Germany). A list of all used primary and secondary 
antibodies as well as further dyes is provided in Table S3. 
 
Analysis of plasma and urine of Gatm+/+ and Gatm-/- mice 
Spot urine of 9 - 12 week old Gatm+/+ (n=6) and Gatm-/- (n=6) mice was collected 
twice per mouse on two different days. After the last sample was taken, mice were 
sacrificed and blood was collected. Metabolites of the creatine synthesis pathway 
(creatinine, creatine, guanidinoacetate), blood glucose, and amino acids were measured 
in urine and plasma. All urine values were normalized to urinary osmolality. For 
measurements urine samples were diluted 1:4. Amino acids were derivatized with 
propylchloroformate/propanol and measured by LC-MS/MS with electrospray ionization 
in positive mode and detection by multiple reaction monitoring (MRM) as recently 
described.4 5 µl of diluted urine or plasma were used for derivatization. Quantification 
was based on calibration curves using 13C,15N-labeled amino acids as internal 
standards. 
Creatinine, creatine, and guanidinoacetate were analyzed by LC-MS/MS with 
electrospray ionization (ESI) in positive mode. An Agilent 1200 SL HPLC hyphenated to 
an AB Sciex (Darmstadt, Germany) 4000 QTrap mass spectrometer working with a 
TurboV electrospray ion source was used. HPLC separation was performed on an 
Atlantis T3 reversed-phase column (150 mm × 2.1 mm i.d., 3 µm, Waters, Eschborn, 
Germany) with mobile phases A (0.1% formic acid in water, v/v) and B (0.1% formic acid 
in acetonitrile, v/v) employing a flow rate of 350 µl/min. The following gradient was used 
with deviating parameters for the positive mode ionization run given in brackets: 0–10 
min linear increase from 0% to 100% B, hold for 2 min (0 min) and return to 0% B at 12.1 
min (10.1 min) and equilibrate for 7 min. The column was kept at 25°C. An injection 
volume of 10 µl was used. Analytes were detected in MRM mode. For the analysis in 
positive mode ionization, two time segments were programmed detecting different 
analytes. Quantification was based on calibration curves using the stable isotope-
labelled analogues as internal standards. Creatinine-d3 was used as internal standard 
for creatine and guanidinoacetate, because they eluted close to each other. 
10 µl internal standard (IS1) solution, containing creatinine-d3 at a concentration of 
100 µM, were added to 10 µl pre-diluted urine and further diluted with water to a final 
volume of 100 µl. A plasma aliquot of 25 µl was spiked with 5 µl IS1 solution and 10 µl 
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surrogate solution containing [U-13C]glucose, [U-13C]lactic acid, and [U-13C]pyruvic acid 
at a concentration of 1 mM. Proteins were precipitated with 150 µl cold methanol and 
samples were centrifuged for 5 min at 4°C and 11200 g. The supernatant was collected 
and dried using a vacuum evaporator (CombiDancer, Hettich AG, Bäch, Switzerland). 
The residue was redissolved in 100 µl water and subjected to analysis. 
p-values for urine analysis: Creatinine = 0.0002, Creatine = 0.0140, 
Guanidinoacetate = 0.0001. p-values for plasma analysis: Creatinine = 0.0026, Creatine 
= 0.0010, Lactate = 0.0031, Serine = 0.0021, Threonine = 0.0017. Data are shown in 
mean values ± standard error of the mean (SEM); “n” stands for the number of 
observations. An unpaired t-test was used to determine statistical significance. As 
multiple parameters were tested in urine and plasma, p-values were corrected according 
to Bonferroni correction (0.05/ n). p-values of 0.0167 (metabolites of the creatine 
pathway), 0.0167 (metabolites of the energy pathway), and 0.0025 (amino acids) were 
accepted to indicate statistical significance. 
 
Immunofluorescence on cryo sections 
Cryosections (5 µm) were mounted on poly-L-lysine slides (Kindler, Freiburg, 
Germany). Prior to incubation with the primary antibodies, sections were incubated in 
0.1% SDS (5 min) for unmasking of epitopes, washed in PBS (2 x 5 min) followed by 
blocking with 5% bovine albumin (10 min). Primary and secondary antibodies were 
diluted in phosphate buffered saline (PBS), pH 7.4, with 0.04% Triton X-100 (Sigma, 
Taufkirchen, Germany). Primary antibodies were applied overnight at 4°C. After washing 
with PBS (2 x 5 min), sections were incubated for 1 h with the secondary antibodies and 
HOE33342 to stain the nuclei. The slides were then washed in PBS (2 x 5 min) and 
mounted with fluorescent-free glycergel mounting medium (DakoCytomation, Hamburg, 
Germany). A list of all used primary and secondary antibodies as well as further dyes is 
provided in Table S3. 
 
Immunofluorescence on paraffin sections 
Human kidney samples were embedded in paraffin and slices (5 µm) were mounted 
on poly-L-lysine slides (Kindler, Freiburg, Germany). To remove paraffin from the 
tissues, slides were put into xylol twice for 10 min each and afterwards rehydrated in an 
alcohol series (99% isopropanol, 95% EtOH, 80% EtOH, 70% EtOH) for 10 min each. 
Then, slices were rinsed with PBS for 5 min and heated at 95°C in citrate buffer (pH 6.0) 
for 15 min to unmask epitopes. The rest of the protocol was performed according to the 
protocol for cryosections. A list of all used primary and secondary antibodies as well as 
further dyes is provided in Table S3. 
 
Masson-Goldner staining on paraffin sections 
For Masson-Goldner staining, sections were deparaffinized as described above. 
Afterwards, slices were incubated in Weigert's Iron Hematoxylin solution for 2 min, 
rinsed in running tap water for 2 min and then briefly put into 0.1% HCl-alcohol solution. 
Subsequently, the slices were rinsed in running tap water for 10 min, incubated in 0.5% 
phosphor tungistic acid for 15 sec and washed three times for 5 min each in distilled 
water, before they were stained in fuchsine acid and Ponceau for 10 min. Next, slides 
were incubated 3 times each for 1 min in 1% glacial ethanoic acid, 20 sec in orange G-
solution, 2 min in 1% glacial ethanoic acid, 4 min in lightgreen-solution and rinsed twice 
in 2% glacial ethanoic acid. Afterwards, slices were dehydrated in 96% isopropanol (20 
sec), 99% isopropanol (twice for 5 min each) and xylol (twice for 10 min each). The 
slides were mounted with xylol-containing DEPEX-medium. 
 
Page 32 of 42
ScholarOne support: 888-503-1050


































































Electron microscopy and immunogold labeling 
Kidney specimens of our Fanconi patients were originally embedded in paraffin. For 
electron microscopy, samples were deparaffinized according to the following protocol: 
xylol (2 x 15 min, 3 x 30 min), 100% ethanol (5 x 15 min), 95% ethanol (15 min), 90% 
ethanol (15 min), 70% ethanol (15 min), 50 % ethanol (15 min), distilled water (2 x 15 
min). After post fixation with 4% glutaraldehyde solution (in 0.1 M Na-cacodylate pH 7.4 
for 60 min) samples were finally rinsed with 0.1 M Na-cacodylate pH 7.4 (2 x 15 min).  
Inducible LLC-PK1 cells were grown on cover slips and induced with tetracycline (1 
µg/ml) for 3 d. Before embedding, cells were fixed using a 2% glutaraldehyde solution in 
0.1 M Na-cacodylate pH 7.4 for about 1 h. Post fixation and dehydration of the samples 
was carried out using the following protocol: rinsing in 0.1 M Na-cacodylate pH 7.4 (3 x 
20 min), 1% OsO4 in 0.1 M Na-cacodylate pH 7.4 (2 h), 0.1 M Na-cacodylate pH 7.4 
cacodylic acid (3 x 20 min), 50% ethanol (15 min), 70% ethanol (15 min), 90% ethanol 
(15 min), 96% ethanol (15 min), 100% ethanol (20 min), acetone (3 x 15 min). Finally, 
samples were embedded in Epon and polymerized at 60°C for 48 h using standard 
protocols. For immunogold labelling, freshly prepared ultrathin sections (70 nm; Ultracut 
UC6; Leica, Wetzlar, Germany) were mounted on grids and treated according to the 
following protocol: 0.1% glycine in PBS (5 min), 1% BSA in glycine solution (5 min), 
primary antibody against GATM in 0.1% BSA in PBS for 1.5 h, 0.1% BSA in PBS (5 x 2 
min), secondary antibody (goat anti rabbit 6 nm gold particles; Aurion, Wageningen, 
Netherlands) in 0.1% BSA in PBS for 1.5 h, 0.1% BSA in PBS (5 x 2 min), PBS (2 x 2 
min), 2% glutaraldehyde in PBS (5 min), PBS (2 x 2 min), distilled water (3 x 2 min). To 
improve contrast, specimens were stained with 2% UAc for 30 min. Ultrathin sections 
were imaged using either an EM902 (Zeiss, Oberkochen, Germany) or a JEM-2100F 
(JEOL, Tokyo, Japan) transmission electron microscope, operated at 80keV (902) or 
200 keV (JEM). Digital micrographs were recorded using a CCD 2k camera (Troendle, 
Moorenweis, Germany) or a CMOS 4k F416 camera (TVIPS, Gauting, Germany).  
 
Quantification of intracellular IL-18 in inducible LLC-PK1 cells 
Quantification of intracellular IL-18 protein content in induced LLC-PK1 cells was 
performed using an ELISA Kit form PromoKine (PK-EL-62816P, Heidelberg, Germany) 
recognizing porcine IL-18. The ELISA was performed according to the manufacturer’s 
protocol. n =3 petri dishes were used for LLC-PK1 cells over-expressing the wildtype 
protein or the T336A mutant, respectively. Cells were induced with tetracycline for 2 
weeks. In the following week, tetracycline was removed from the medium. After 3 weeks, 
cells were lysed and intracellular content of IL-18 was quantified. Data were normalized 
to total protein content determined by Bradford assay. p-value = 0.0012. Data are shown 
as mean values ± standard error of the mean (SEM); “n” stands for the number of 
observations. An unpaired t-test was used to determine statistical significance and a p-
value of 0.05 was accepted to indicate statistical significance. 
 
Determination of protein concentration with Bradford assay 
Frozen cell pellets were used to determine protein concentration of inducible LLC-
PK1 cells. Cell pellets were resuspended in sample buffer containing DTT, 86% glycerol, 
10 % SDS, 0.5 M tris(hydroxymethyl)aminomethane (TRIS) pH 6.8, 0.5 M MgCl2, and 25 
U/µl benzonase. For quantification, different BSA solutions of known concentration were 
prepared. All samples were diluted in Bradford reagent (1:100) and transferred to a 96-
well plate. After incubating for 15 min in the dark, the absorption at 595 nm was 
measured in a microplate reader (Bio-Rad, Hercules, USA). Protein concentrations were 
determined on the basis of the standard linear slope from the BSA standards. 
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Measurement of extracellular LDH activity 
For over-expression of wildtype GATM or T336A mutant proteins, respective LLC-
PK1 cells were induced with tetracycline for 3 weeks (plus the days shown on the x-axis 
in the graph of Fig. 4C). Extracellular LDH activity as a surrogate marker of cytolysis was 
measured using Pierce™ LDH cytotoxicity assay kit (Thermo Fisher Scientific, Bonn, 
Germany). The experiments were carried out in triplicate and normalized to the total 
cellular protein amounts determined by Bradford assay. Significant differences were 
determined in IBM SPSS 23 using two-way ANOVA with post-hoc Student´s t-tests 
corrected for multiple testing by the Bonferroni method (0.05/n = 0.0167). p-values were 
0.0039 (day 2), <0.0001 (day 3), and <0.0001 (day 4). Data are shown as mean values ± 
standard error of the mean (SEM); “n” stands for the number of observations. 
 
Live cell imaging of mitochondrial reactive oxygen species production 
3.5x105 LLC-PK1 cells were seeded on a 30-mm cover glass coated with poly-L-
lysine. When confluent, cells were incubated with 1 µg/ml tetracycline for 48 h to induce 
expression of wildtype- or mutant T336A GATM. Reactive oxygen species (ROS) 
production was measured by incubating the cells with 5 µM CellROX Deep Red (Life 
Technologies) for 30 min at 37°C. The rate of incre ase in fluorescence signal was taken 
as proportional to the rate of ROS production. Cells were imaged at 37°C using a Leica 
SP5 automated inverted confocal laser scanning microscope and a 63x objective. 
CellROX was excited at 633 nm and light was collected between 638 nm and 737 nm. 
Images were acquired every 10 min to minimize laser-induced photo-toxicity for a 
maximal duration of 40 min. 7 coverslips of induced wildtype and 6 of mutant T336A 
GATM were imaged. 30 fields were acquired per coverslip using the Matrix screener 
Leica software and normalized to the initial fluorescence after incubation (30 min with 
CellROX). Images were analyzed using Image J software (https://imagej.nih.gov/ij/). The 
results are presented as mean values ± SEM. Statistical analysis was performed using 
Prism 6 (http://www.graphpad.com) by comparing the rates of ROS production between 




Male, wildtype C57Bl/6 mice (n=8, age 10 weeks, Jackson Laboratories) were 
randomly assigned to either a group nourished with a diet consisting of bread and tap 
water (low creatine, high carbohydrate diet) or a group with an additional supplement of 
1% (w/w) creatine (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) in the drinking 
water. After sacrificing the mice kidneys were removed, divided into halves, then 
immediately frozen in liquid nitrogen and stored at -80°C until further experimentation. 
Frozen mouse kidneys were pulverized in liquid nitrogen using a mortar and RNA was 
isolated using RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s recommendations. RNA was quantified using the NanoDrop 2000c 
spectrophotometer (Peqlab Biotechnologie GmbH, Erlangen, Germany) and its quality 
was assessed by imaging on 1% agarose gel. RNA was then transcribed to cDNA using 
Reverse Transcription System (Promega, Madison, WI) according to the manufacturer’s 
recommendations. Real-time PCR was performed as described above using cDNA, 
SYBR® Green mix (Roche Diagnostics GmbH, Mannheim, Germany) and primers for 
mouse Gatm or β-actin (Table S4). For real-time PCR, a Light Cycler 480 (Roche 
Diagnostics, Rotkreuz, Switzerland) was employed according to the manufacturer’s 
recommendations. Quality and size of the amplicon were further verified by visualization 
on 3% agarose gels. 
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Frozen mouse kidneys were weighed, then pulverized in liquid nitrogen using a 
mortar and proteins eluted by incubation in 3 µl/mg kidney tissue of a lysis-buffer 
containing RIPA-buffer (1% Igepal CA-630, 0.5% sodium-desoxycholate, 0.1% SDS in 
PBS), 200 mM PMSF (1/200 v/v) and EDTA-free protease inhibitor cocktail set III (1/100 
v/v, Calbiochem, San Diego, CA) for 20 min on ice. Samples were centrifuged at 14.800 
rpm for 10 min at 4°C and supernatants stored at -2 0°C until further analysis. The 
protein content of the samples was quantified in 96-well plates (Nuncleon Delta Surface, 
NUNC A/S, Roskilde, Denmark) according to Bradford using Bio-Rad protein assay (Bio-
Rad Laboratories GmbH, Muenchen, Germany) and Bio-Rad 550 Microplate Reader 
(Bio-Rad) according to the manufacturer’s recommendations. Equal amounts of proteins 
in Laemmli-buffer (Bio-Rad) including 2-mercaptoethanol 1/20 (v/v, Merck Schuchard, 
Hohenbrunn, Germany) were cooked for 5 min, separated by 10% SDS-PAGE and 
transferred to a PVDF blotting membrane (Amersham Hybond). The membrane was 
blocked by incubation with 5% fat-free dry milk-powder (w/v, AppliChem GmbH, 
Darmstadt, Germany) in PBS-Tween for 1 h at room temperature followed by incubation 
with primary antibody polyclonal rabbit anti-GATM (1/2000 v/v, Proteintech, Manchester, 
UK) in 1.5% BSA in PBS-Tween at 4oC overnight. The secondary antibody donkey anti-
rabbit IgG-horseradish peroxidase (HRP, 1/5000, v/v, Santo Cruz Biotechnology) in 1% 
PBS-Tween was incubated for 1 h at room temperature and protein bands developed 
using Western Blot Luminol Reagent (Santa Cruz Biotechnology, Heidelberg, Germany) 
and visualized in Fusion Fx7 (Vilber Lourmat, Marne-la-Vallee, France). The membranes 
were stripped from bound antibodies by applying Restore Western Blot Stripping Buffer 
(Thermo Scientific, Rockford, IL) for 15 min at room temperature, washed, blocked as 
described above and the house-keeping protein was detected using as primary antibody 
rabbit anti-mouse beta-actin (1/5000 v/v, Sigma-Aldrich, Taufkirchen, Germany) in 1.5% 
BSA-PBS-Tween at 4°C overnight and as secondary ant ibody donkey anti-rabbit IgG-
HRP (1/5000, v/v, Santa Cruz Biotechnology, Heidelberg, Germany) in 1% PBS-Tween 
for 1 h at room temperature. Quantification of Gatm and beta-actin was performed with 
ImageJ. 
p-values: RT-PCR = 0.0125, Western blot quantification = 0.029 . Data are shown 
in mean values ± standard error of the mean (SEM); “n” stands for the number of 
observations. An unpaired t-test was used to determine statistical significance and a p-
value of 0.05 was accepted to indicate statistical significance. 
 
Structural studies and data availability 
To test the hypothesis of mutation-mediated aggregation of GATM, we performed 
molecular dynamics simulations on the wildtype monomer and on the four mutants. 
Modelling of possible protein-protein interaction surfaces (GRAMM-X; 
http://vakser.bioinformatics.ku.edu/resources/gramm/grammx/) started with the structure 
of the wildtype monomer (pdb: 1JDW at http://www.rcsb.org/pdb/home/home.do).  
We utilized publicly available GATM crystal structures (i.e. 1JDW subunit A) to 
simulate the effect of all mutations recognized in our patients. In order to test the 
hypothesis of mutation-mediated destabilization of the region around B4, we performed 
molecular dynamics simulations on the wildtype monomer and on the four mutants, 
starting from the coordinates of 1JDW subunit A. Each simulation lasted for 40 ns. At the 
end of the simulations (after 40 ns) superposing all the mutants on the wildtype protein 
results in Cα root mean square displacement (r.m.s.d.) from 1.12 to 1.47 Å (from 1.17 to 
1.72 Å if we limit the superposition on the region around the B4 surface). The lower 
differences with respect to the wildtype in T336A mutant could be related to the fact that 
this mutation may require more time (with respect to the 40 ns of the simulation) to 
propagate its effect. 
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In order to test the possibility of stable dimerization based on the B4 surface, we 
performed two additional molecular dynamics simulations on the wildtype and on the 
P341L B4-based dimers as modelled by the program GRAMM-X. The P341L mutant 
was chosen being the one with the higher overall r.m.s.d. respect to wildtype GATM 
during the previous simulations, therefore the most variable during the simulation time. 
Along the simulation, the wildtype dimer analyzed by the program PISA 
(www.ebi.ac.uk/pdbe/pisa/) adopts different configurations compatible with stable and 
unstable dimeric assemblies. Interestingly, the P341L dimer promptly evolves toward 
stability (after 10 ns) that is maintained along the remaining simulation time. Such 
simulation results show, on one hand, how the B4 interface is prone to protein-protein 
interaction also in the wildtype protein and, on the other hand, how it is sufficient for only 
a point mutation (P341L) to shift the B4 based monomer-dimer equilibrium towards 
another stable quaternary assembly. This analysis, as the one shown before, clearly 
supports the hypothesis that the mutation induced structural rearrangements of the B4 
surface do promote a new protein-protein interaction surface that can lead to linear 
aggregation of GATM. 
 
For cell expression studies, the human GATM coding region obtained from a 
Trueclone full length cDNA clone (sc321307, 
https://www.ncbi.nlm.nih.gov/nuccore/NM_001482.1; Origene Technologies; Rockville, 
MD, USA) was used. 
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Graph illustrating decline in kidney function in GATM related renal Fanconi 
syndrome and kidney failure and age at kidney transplantation. Data from affected 
and genotyped individuals are shown. In six individuals ( , , , , , ) connecting 
lines indicate serial measurements. In another six individuals ( ) single creatinine 
measurements are plotted. In eight individuals ( ) age at kidney transplantation is 
presented. The horizontal dashed line indicates normal plasma creatinine (110 µmol/l) 
for an average adult person. Note normal plasma creatinine in the youngest child and 
ensuing kidney failure in individuals from adolescence on with need for transplant as 
early as 30 years of age. 
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Analysis of urine and plasma from Gatm+/+ and Gatm-/- mice: (A) Urinary excretion of 
amino acids as well as glucose excretion was not different between Gatm+/+ and Gatm-/- 
mice (n=6/6, values normalized to osmolyte excretion), which indicates that knockout 
animals do not suffer from renal Fanconi syndrome. (B) In plasma, the concentrations of 
most amino acids and glucose (non-fasted animals) were similar between the two 
groups. (C and D) As expected, urine and plasma concentrations of creatine and 
creatinine were very low in Gatm-/- mice, since the endogenous creatine synthesis 
pathway is disturbed. The residual creatine and creatinine amounts result from creatine 
absorption from food. Interestingly, the concentration of guanidinoacetate, the direct 
product of Gatm activity, was normal in plasma whereas the urinary excretion was 
decreased in knockout mice. (E) Urinary excretion of pyruvate, lactate and glucose. (F) 
Plasma concentration of lactate was lower in Gatm-/- mice whereas pyruvate 
concentration was not different. ND = not detectable.  
 









Creatinine positive –P1  114.0 86.0 150 26 
Creatinine d3 positive –P1 117.0 89.0 150 26 
Creatine positive –P1 132.2 90.0 150 21 
Guanidinoacetate positive –P1 118.1 43.0 150 36 
 
DP - declustering potential, P1 - period 1, P2 - period 2 
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1H-NMR spectroscopy to determine brain (grey matter) creatine content: Note, 
normal creatine (total) peak (indicated by arrow) in control volunteer (top) and GATM 
patient (bottom), providing also evidence for GATM’s catalytical (i.e. enzymatic) 
competence. Quantification in the volunteer showed a total creatine of 5.8 mM and 5.0 
mM in grey and white matter, respectively. The GATM patient showed 6.1 mM and 4.4 
mM in grey and white matter, respectively. 
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Laboratory findings of a young patient with GATM-related renal Fanconi syndrome 
 
Substance Laboratory finding Age appropriate reference 
ranges 
Plasma values 
Sodium 143 mmol/L 133 - 146 mmol/L 
Potassium 3.6 mmol/L 3.5 - 5.5 mmol/L 
Chloride 108 mmol/L 100 - 108 mmol/L 
Total CO2 17 mmol/L 20 - 30 mmol/L 
Urea 5.3 mmol/L 2.5 - 6.0 mmol/L 
Creatinine 22 µmol/L 16 - 33 µmol/L 
Calcium 2.47 mmol/L 2.17 - 2.44 mmol/L 
Magnesium 0.95 mmol/L 0.66 - 1.00 mmol/L 
Phosphate 1.16 mmol/L 1.2 - 2.1 mmol/L 
Albumin 49 g/L 34 - 42 g/L 
Alkaline Phosphatase (ALP) 413 U/L 145 - 320 U/L 
Alanine Transaminase (ALT) 30 U/L 5 - 45 U/L 
Total bilirubin 5 µmol/L < 18 µmol/L 
Intact PTH 2.5 pmol/L 0.7 - 5.6 pmol/L 
Urine values 
Glucose Stix result positive +++ negative 
Glucose 8.0 mmol/L  
Phosphate 8.86 mmol/L  
Creatinine 0.5 mmol/L  
Phosphate/Creatinine ratio 17.72 1.2 - 14 
Tubular Reabsorption of Phosphate 66 % 70 - 100 % 
TmP/GFR 0.77 mmol/L 1.10 - 2.70 mmol/L 
Urine amino acids 
Glycine/Creatinine ratio 5090 µmol/mmol 250 - 626 µmol/mmol 
Serine/Creatinine ratio 2355 µmol/mmol 20 - 100 µmol/mmol 
Threonine/Creatinine ratio 2129 µmol/mmol 10 - 45 µmol/mmol 
Proline/Creatinine ratio 1864 µmol/mmol 0 - 3 µmol/mmol 
Leucine/Creatinine ratio 320 µmol/mmol 3 - 10 µmol/mmol 
Isoleucine/Creatinine ratio 141 µmol/mmol 2 - 10 µmol/mmol 
Valine/Creatinine ratio 738 µmol/mmol 2 - 8 µmol/mmol 
Alanine/Creatinine ratio 3092 µmol/mmol 30 - 80 µmol/mmol 
Glutamine/Creatinine ratio 4159 µmol/mmol 30 - 120 µmol/mmol 
Arginine/Creatinine ratio 166 µmol/mmol 2 - 10 µmol/mmol 
Ornithine/Creatinine ratio 230 µmol/mmol 2 - 10 µmol/mmol 
Lysine/Creatinine ratio 1614 µmol/mmol 5 - 30 µmol/mmol 
Cystine/Creatinine ratio 226 µmol/mmol 5 - 25 µmol/mmol 
Methionine/Creatinine ratio 46 µmol/mmol 3 - 15 µmol/mmol 
Taurine/Creatinine ratio 184 µmol/mmol 30 - 105 µmol/mmol 
Phenylalanine/Creat ratio 345 µmol/mmol 5 - 15 µmol/mmol 
Tyrosine/Creatinine ratio 716 µmol/mmol 5 - 15 µmol/mmol 
Tryptophan/Creatinine ratio 193 µmol/mmol 1 - 5 µmol/mmol 
Histidine/Creatinine ratio 1909 µmol/mmol 100 - 300 µmol/mmol 
Aspartate/Creatinine ratio 82 µmol/mmol 10 - 35 µmol/mmol 
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Glutamate/Creatinine ratio 86 µmol/mmol 0 - 3 µmol/mmol 
 
Albumin/Creatinine ratio 54.3 mg/mmol 1.5 - 8.7 mg/mmol 
NAG/Creatinine ratio 392 U/mmol 2 - 22 U/mmol 
Retinol Binding Protein/Creatinine ratio 10420 µg/mmol 2.7 - 103 µg/mmol 
 
Laboratory findings from an affected and genotyped 18 month old child before start of 
treatment illustrating presence of renal Fanconi syndrome. Note normal plasma 
creatinine and normal PTH. Note typical signs of renal Fanconi syndrome, i.e. 
glucosuria, hyperphosphaturia and hypophosphatemia, generalized hyperaminoaciduria, 
low molecular weight proteinuria, metabolic acidosis and slightly elevated alkaline 





PCR primer sequences and PCR conditions for expression studies 
 











































Antibodies and conditions for imaging studies. IF: immunofluorescence, WB: Western 
blot. 
 
Antibody/Dye (Usage) Species Dilution Manufacturer 
anti-GATM (IF, WB) rabbit 1:200 (IF) 
1:2000 (WB) 
Proteintech, Manchester, UK 
anti-α-SMA (IF) mouse 1:600 Abcam, Cambridge, UK 
anti-β-actin (WB) rabbit 1:5000 Sigma-Aldrich, Taufkirchen, 
Germany 
Alexa Fluor® 555 anti rabbit (IF) donkey 1:400 Invitrogen, Karlsruhe, 
Germany 
Alexa Fluor® 488 anti mouse (IF) donkey 1:400 Invitrogen, Karlsruhe, 
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anti rabbit IgG-HRP (WB) donkey 1:5000 Santa Cruz, Heidelberg, 
Germany 
MitoTracker Orange CMTMRos 
(IF) (Stock: 1 mM) 
 1:5000 Invitrogen, Karlsruhe, 
Germany 
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